Zaeske Adam H.
Known title: CHIEF COMMERCIAL OFFICERCIK: 0002064712
Associated companies
Transaction History
| HRMY | ▲ Buy | Option Exercise | 7,500 | $0 | 4/7/2026 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 3,173 | $88K | 4/7/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 7,500 | $0 | 4/7/2026 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 3,173 | $88K | 4/7/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook
HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook. HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.